ASBP earnings analysis
What we found in ASBP's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q does not include current-quarter income statement, balance-sheet, cash-flow, segment, or quantitative guidance data, so operating trends cannot be assessed from the filing. The principal negative signal is ineffective disclosure controls as of June 30, 2026, specifically including recapitalization accounting. Aspire raised $20,000,000 through issuance of 26,250 preferred shares during the six months ended June 30, 2026, while additional common-share issuances create meaningful dilution risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Raised $20 million in preferred financing
- Aspire issued 26,250 shares of Series A Convertible Preferred Stock for gross proceeds of $20,000,000 during the six months ended June 30, 2026, providing additional financing.
- No share repurchases
- The filing reports no equity repurchases during either the three or six months ended June 30, 2026, preserving cash that otherwise could have been used for buybacks.
- No insider trading-plan changes
- The company disclosed that no directors or officers adopted, modified, or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the three and six months ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material weakness in disclosure controls
- Management and the CEO and CFO concluded that disclosure controls and procedures were not effective as of June 30, 2026, including controls surrounding complex accounting areas such as the recapitalization.
- Substantial equity dilution
- The six-month financing and other transactions included 26,250 preferred shares, 26,333 common incentive shares, 21,525 common shares issued to lenders, and 207 true-up shares, creating dilution risk for existing holders.
- No formal risk-factor update
- The company states that there were no material changes to the risk factors in its December 31, 2025 Form 10-K. Accordingly, no new formal risk-factor changes were identified in this 10-Q.
What they said about what is next.
The 10-Q does not provide quantitative revenue or EPS guidance; outlook was not provided in the extracted filing.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- Aspire Biopharma reported a substantial improvement in revenue and a notable decrease in net loss compared to the prior year, indicating an evolving operational trajectory. However, management highlighted ongoing…
- 10-K · March 30, 2026
- Aspire Biopharma reports positive early clinical and regulatory progress for its patent-pending sublingual delivery technology (completed a July 2025 bioavailability study with final report received September 5, 2025)…
- 10-Q · May 14, 2025
- Aspire Biopharma reported no revenue and a net loss of $15,941,328 for the quarter ended March 31, 2025, driving diluted EPS of $(0.42) compared with a net loss of $230,970 (EPS $(0.01)) in the prior-year quarter. Cash…
- 10-K · March 11, 2024
- PowerUp Acquisition Corp. is pursuing a merger with Visiox Pharmaceuticals, focusing on late-stage pharmaceutical opportunities due to favorable market conditions. The company has extended its business combination…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ASBP makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever